Dual Targeting of Mutant p53 and SNRPD2 via Engineered Exosomes Modulates Alternative Splicing to Suppress Ovarian Cancer

ABSTRACT Mutation of the tumor suppressor gene TP53 promotes ovarian cancer progression and therapeutic resistance. Whether mutant p53 (mtp53) regulates alternative splicing and how this regulation can be exploited for cancer therapy remain unclear. Here, small nuclear ribonucleoprotein D2 polypepti...

Descripció completa

Dades bibliogràfiques

Autors principals:	Wei Zhao, Qian Hao, Yu Gan, Jing Tong, Xiaodan Chen, Shuran Tan, Ruiwen Ruan, Yingdan Huang, Mingming Cao, Jun Deng, Tao Han, Getao Shi, Bo Gao, Yu Zhang, Xiang Zhou
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2026-03-01
Col·lecció:	Advanced Science
Matèries:	alternative splicing engineered exosomes p53 SNRPD2 targeted therapy
Accés en línia:	https://doi.org/10.1002/advs.202513369
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!